Ad
related to: pfizer analgesic
Search results
Results From The WOW.Com Content Network
PF-05089771 is a selective, small-molecule Na v 1.7 and Na v 1.8 voltage-gated sodium channel blocker under development by Pfizer as a novel analgesic. [1] [2] [3] As of June 2014, it has completed phase II clinical trials for wisdom tooth removal and primary erythromelalgia. [4]
PD-217,014 is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α 2 δ calcium channels (1 and 2).It was developed as a potentially more potent successor to gabapentin and pregabalin, along with several other analogues such as atagabalin and 4-methylpregabalin, but while PD-217,014 produces visceral analgesic effects in animal studies with higher potency and ...
4-Methylpregabalin is a drug developed by Pfizer and related to pregabalin, which similarly acts as an analgesic with effectiveness against difficult to treat "atypical" pain syndromes such as neuropathic pain.
Pregabalin, sold under the brand name Lyrica among others, is an anticonvulsant, analgesic, and anxiolytic amino acid medication used to treat epilepsy, neuropathic pain, fibromyalgia, restless legs syndrome, opioid withdrawal, and generalized anxiety disorder (GAD).
Bengay, spelled Ben-Gay before 1995, is a topical analgesic heat rub for temporary relief from muscle and joint pain associated with arthritis, bruises, simple backaches, overuse, sprains and strains. [1]
Tanezumab was discovered and developed by Rinat Neuroscience [2] and was acquired by Pfizer in 2006. In 2009 there was a Phase III trial for knee pain due to osteoarthritis (OA). [3] Another Phase III trial for hip pain in OA [4] was halted in June 2010 when some patients needed hip replacement. [5]
It was under development by Pfizer as a pharmaceutical medication due to its hypothesized anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity. It reached phase-III clinical trials for treatment of generalized anxiety disorder; however, the trials were terminated by the manufacturer.
The analgesic effects of the drugs had been exaggerated. Reuben was also a former paid spokesperson for Pfizer. Although from 2002 to 2007 Pfizer underwrote much of Dr. Reuben's research and "many of his trials found that Celebrex and Lyrica, Pfizer drugs, were effective against postoperative pain," Pfizer was not aware of the fraudulent data.